Chemical biology and pharmacology of histone lysine methylation inhibitors
SH Barghout, RAC Machado… - Biochimica et Biophysica …, 2022 - Elsevier
Histone lysine methylation is a post-translational modification that plays a key role in the
epigenetic regulation of a broad spectrum of biological processes. Moreover, the …
epigenetic regulation of a broad spectrum of biological processes. Moreover, the …
Optical genome mapping reveals the complex genetic landscape of myeloma
A Giguère, I Raymond-Bouchard, V Collin, JS Claveau… - Cancers, 2023 - mdpi.com
Simple Summary Myeloma is a hematological cancer characterized by numerous genetic
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …
abnormalities currently identified using fluorescent in situ hybridization (FISH). However …
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
AG Dosne, X Li, MM Luo, I Nnane… - British Journal of …, 2023 - Wiley Online Library
Aim A population pharmacokinetic (PPK) model was developed to characterize
pharmacokinetics (PK) of subcutaneous or intravenous daratumumab administration in a …
pharmacokinetics (PK) of subcutaneous or intravenous daratumumab administration in a …
[HTML][HTML] Стратификация больных множественной миеломой: современное состояние вопроса и дальнейшие перспективы
АЮ Аксенова, АС Жук, ЕИ Степченкова… - Клиническая …, 2022 - cyberleninka.ru
В последние годы наблюдается существенный прогресс в улучшении выживаемости
без прогрессирования (ВБП) и качества жизни больных множественной миеломой …
без прогрессирования (ВБП) и качества жизни больных множественной миеломой …
Impact of bortezomib on 1q21+ in multiple myeloma: A meta-analysis of treatment outcomes and prognostic implications
X Zheng, S Lin, K Lu, J Hou, T Liu - Oncology Letters, 2024 - spandidos-publications.com
The gain of chromosomal region 1q21 is a significant risk factor in multiple myeloma (MM)
and is associated with poor prognosis. The introduction of bortezomib has notably improved …
and is associated with poor prognosis. The introduction of bortezomib has notably improved …
[HTML][HTML] Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five …
M Shokripour, SE Hosseini, N Omidifar… - Iranian Journal of …, 2024 - ncbi.nlm.nih.gov
Background: The aggregation of clonal plasma cells causes plasma cell neoplasms, which
vary in severity and clinical outcomes. The present research focused on the epidemiological …
vary in severity and clinical outcomes. The present research focused on the epidemiological …
Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology
Y Wang, M Wang, B Chu, M Lu, L Shi, S Gao… - Cancer Pathogenesis …, 2024 - mednexus.org
Background: Multiple myeloma (MM) is a heterogeneous plasma-derived hematopoietic
malignancy with complex genetic mutation contributing to the pathogenesis. Though gene …
malignancy with complex genetic mutation contributing to the pathogenesis. Though gene …
[HTML][HTML] Stratification of Patients with Multiple Myeloma: State-of-the-Art and Prospects
AY Aksenova, AS Zhuk, EI Stepchenkova… - Clinical …, 2022 - old.bloodjournal.ru
In recent years, there has been a substantial progress in improving progression-free survival
(PFS) and quality of life of multiple myeloma (MM) patients. This has become possible …
(PFS) and quality of life of multiple myeloma (MM) patients. This has become possible …
Cytogenetic and Molecular Cytogenetic Markers in Patients with Multiple Myeloma-Prognostic Significance//Цитогенетични и молекулярно-цитогенетични маркери …
В Митева - 2023 - repository.mu-varna.bg
Множественият миелом е инвалидизиращо заболяване представляващо значителен
здравен проблем. В проучването са включени 110 пациенти анализирани в …
здравен проблем. В проучването са включени 110 пациенти анализирани в …
Untersuchungen zu klinischen und biologischen Eigenschaften von medullären und extramedullären Plasmazelldyskrasien unter besonderer Berücksichtigung von …
D Balci-Hakimeh - 2022 - refubium.fu-berlin.de
Das extramedulläre Myelom (MM-EM) ist eine seltene, aber klinisch bedeutsame
Manifestation des Multiplen Myeloms (MM), die sich hinsichtlich des klinischen Verlaufs und …
Manifestation des Multiplen Myeloms (MM), die sich hinsichtlich des klinischen Verlaufs und …